Nurix Therapeutics (NRIX) Assets Average (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Assets Average data on file, last reported at $662.1 million in Q1 2026.

• Quarterly Assets Average rose 3.1% year-over-year to $662.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $662.1 million (up 3.1% YoY) and the FY2025 annual result came in at $678.7 million, up 32.44% from the prior year.
• Assets Average climbed to $662.1 million in Q1 2026 per NRIX's latest filing, from $605.3 million in the prior quarter.
• Across five years, Assets Average topped out at $662.1 million in Q1 2026 and bottomed at $329.4 million in Q3 2023.
• The 5-year median for Assets Average is $438.0 million (2022), against an average of $474.9 million.
• The widest annual swing landed in 2023, when Assets Average fell 24.23%; it then jumped 92.2% in 2025.
• Tracing NRIX's Assets Average over 5 years: stood at $438.0 million in 2022, then retreated by 24.23% to $331.9 million in 2023, then soared by 78.21% to $591.5 million in 2024, then increased by 2.34% to $605.3 million in 2025, then climbed by 9.39% to $662.1 million in 2026.
• Per Business Quant, the three latest NRIX Assets Average figures stand at $662.1 million (Q1 2026), $605.3 million (Q4 2025), and $557.0 million (Q3 2025).

Peer Comparison